Antigens, CD19

"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.

Descriptor ID	D018941
MeSH Number(s)	D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
Concept/Terms	Antigens, CD19 Antigens, CD19 CD19 Antigens B Cell Antigen CD19 CD19 Antigen Antigen, CD19

Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".

Chemicals and Drugs [D]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, CD [D23.050.301.264.035]
Antigens, CD19 [D23.050.301.264.035.119]
Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
Antigens, CD19 [D23.050.301.264.051.119]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Antigens, CD19 [D23.050.301.500.600.200]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Antigens, CD19 [D23.050.705.552.600.200]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, CD [D23.101.100.110]
Antigens, CD19 [D23.101.100.110.119]
Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
Antigens, CD19 [D23.101.100.150.119]

Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.

Bar chart showing 9 publications over 8 distinct years, with a maximum of 2 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2006	1	0	1
2010	0	1	1
2011	0	1	1
2014	0	2	2
2015	1	0	1
2016	0	1	1
2019	0	1	1
2022	0	1	1

Below are the most recent publications written about "Antigens, CD19" by people in Profiles.

Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, Anagnostou T, Alperovich A, Shah N, Fraint E, Lin RJ, Scordo M, Batlevi CL, Besser MJ, Dahi PB, Danylesko I, Giralt S, Imber BS, Jacoby E, Kedmi M, Nagler A, Palomba ML, Roshal M, Salles GA, Sauter C, Shem-Tov N, Shimoni A, Yahalom J, Yerushalmi R, Shah GL, Avigdor A, Perales MA, Shouval R. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023 01; 37(1):154-163.

View in: PubMed
Garimalla S, Nguyen DC, Halliley JL, Tipton C, Rosenberg AF, Fucile CF, Saney CL, Kyu S, Kaminski D, Qian Y, Scheuermann RH, Gibson G, Sanz I, Lee FE. Differential transcriptome and development of human peripheral plasma cell subsets. JCI Insight. 2019 05 02; 4(9).

View in: PubMed
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016 06; 6(6):664-79.

View in: PubMed
Krishnan V, Xu X, Kelly D, Snook A, Waldman SA, Mason RW, Jia X, Rajasekaran AK. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. Mol Pharm. 2015 Jun 01; 12(6):2101-11.

View in: PubMed
Adams CM, Eischen CM. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer. Cancer Res. 2014 Jul 15; 74(14):3923-34.

View in: PubMed
Weinstein JS, Bertino SA, Hernandez SG, Poholek AC, Teplitzky TB, Nowyhed HN, Craft J. B cells in T follicular helper cell development and function: separable roles in delivery of ICOS ligand and antigen. J Immunol. 2014 Apr 01; 192(7):3166-79.

View in: PubMed
Kavuru MS, Malur A, Marshall I, Barna BP, Meziane M, Huizar I, Dalrymple H, Karnekar R, Thomassen MJ. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J. 2011 Dec; 38(6):1361-7.

View in: PubMed
Coffey F, Manser T. Expression of cellular FLIP by B cells is required for their participation in an immune response. J Immunol. 2010 May 01; 184(9):4871-9.

View in: PubMed
Rumfelt LL, Zhou Y, Rowley BM, Shinton SA, Hardy RR. Lineage specification and plasticity in CD19- early B cell precursors. J Exp Med. 2006 Mar 20; 203(3):675-87.

View in: PubMed
Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995 Aug; 18(5-6):385-97.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement